• Hypertension

Moexipril/hydrochlorothiazide Generic Name & Formulations

General Description

Moexipril HCl, hydrochlorothiazide; 7.5mg/12.5mg, 15mg/12.5mg, 15mg/25mg; scored tabs.

Pharmacological Class

ACE inhibitor + diuretic.

How Supplied

Contact supplier

Moexipril/hydrochlorothiazide Indications


Hypertension (not for initial therapy).

Moexipril/hydrochlorothiazide Dosage and Administration


Take 1 hour before a meal. Switching from monotherapy with either component: 1 tab once daily, then adjust; usual max 30mg/50mg per day. Allow 2–3 weeks for titration of HCTZ component. Or, substitute for individually-titrated components.


Not established.

Moexipril/hydrochlorothiazide Contraindications


History of ACEI-associated angioedema. Anuria. Sulfonamide allergy. Concomitant aliskiren in patients with diabetes.

Moexipril/hydrochlorothiazide Boxed Warnings

Boxed Warning

Fetal toxicity.

Moexipril/hydrochlorothiazide Warnings/Precautions


Fetal toxicity may develop; discontinue if pregnancy is detected. Renal impairment (CrCl ≤40mL/min): not recommended. Discontinue if angioedema, laryngeal edema, jaundice, or marked elevation of hepatic enzymes occurs. Renal or hepatic dysfunction. Salt/volume depletion. CHF. Ischemic heart disease. Aortic or renal artery stenosis. Cerebrovascular disease. Dialysis (esp. high-flux membrane). Surgery. Diabetes. Gout. Asthma. Postsympathectomy. Monitor WBC counts in renal or collagen vascular disease. SLE. Acute myopia and secondary angle-closure glaucoma. Monitor electrolytes and renal function. Elderly. Neonates. Pregnancy (Cat.D); monitor. Nursing mothers: not recommended.

Moexipril/hydrochlorothiazide Pharmacokinetics

See Literature

Moexipril/hydrochlorothiazide Interactions


See Contraindications. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Concomitant aliskiren in renal impairment (CrCl <60mL/min): not recommended. May cause hyperkalemia with K+ sparing diuretics, K+ supplements, or Kcontaining salt substitutes. Hypokalemia with corticosteroids, ACTH, amphotericin B. May increase lithium, digitalis, diazoxide toxicity. Alcohol, CNS depressants may increase orthostatic hypotension. Adjust antidiabetic, antigout medications. Potentiates nondepolarizing muscle relaxants. Antagonizes norepinephrine. May be antagonized by, and renal toxicity potentiated by NSAIDs (including COX-2 inhibitors): monitor renal function in elderly and/or volume-depleted. May interfere with parathyroid tests. Reduced absorption with cholestyramine and colestipol resins. Nitritoid reactions with concomitant injectable gold (eg, sodium aurothiomalate); rare.

Moexipril/hydrochlorothiazide Adverse Reactions

Adverse Reactions

Cough, dizziness, fatigue, headache, hyperuricemia, electrolyte disturbances, hyperglycemia, rash, facial flushing, GI upset, angioedema (eg, intestinal), orthostatic hypotension, neutropenia; rare: hepatic failure.

Moexipril/hydrochlorothiazide Clinical Trials

See Literature

Moexipril/hydrochlorothiazide Note


Formerly known under the brand name Uniretic.

Moexipril/hydrochlorothiazide Patient Counseling

See Literature